Semaglutide
Semaglutide is a long-acting GLP-1 receptor agonist with 94% homology to native GLP-1, engineered for enhanced stability and once-weekly administration in metabolic research.
Semaglutide binds to GLP-1 receptors with high affinity, stimulating glucose-dependent insulin secretion while suppressing glucagon release and slowing gastric emptying for prolonged satiety signaling.
Research demonstrates 14.9% average weight reduction and 1.5-2.0% HbA1c reduction, with studies showing significant appetite suppression through hypothalamic POMC neuron activation and reduced food intake by 35%.
Clinical data reveals cardiovascular benefits beyond metabolic effects, including 26% reduction in major adverse cardiovascular events and improved endothelial function markers.
Semaglutide provides sustained GLP-1 activation, clinically significant weight loss, and cardiovascular protection, establishing it as a cornerstone compound for research in obesity, type 2 diabetes, and cardiometabolic disease.
Composition: Semaglutide (5mg, 10mg)